On Friday, Natural Grocers by Vitamin Cottage Inc (NYSE:NGVC)’s shares inclined 24.20% to $26.74.
Natural Grocers by Vitamin Cottage, Inc. (NGVC) declared its results for the third quarter and year to date fiscal 2015 periods ended June 30, 2015. The Company also updated its outlook for fiscal 2015 and offered its initial outlook for fiscal 2016.
In addition to presenting the financial results of Natural Grocers by Vitamin Cottage, Inc. and its auxiliaries (collectively, the Company) for the third quarter and year to date fiscal 2015 and 2014 in conformity with U.S. generally accepted accounting principles (GAAP), the Company is presenting EBITDA, which is a non-GAAP financial measure. The reconciliation from GAAP to this non-GAAP financial measure is offered at the end of this earnings release.
Natural Grocers by Vitamin Cottage, Inc., together with its auxiliaries, operates natural and organic groceries and dietary supplement retail stores in the United States. The company’s stores offer natural and organic grocery products, such as organic produce products; bulk food and private label products; dry, frozen, and canned groceries; meat and seafood products; dairy products and dairy substitutes; prepared foods; bread and baked products; and beverages.
Coty Inc (NYSE:COTY)’s shares dropped -0.67% to $26.73.
Coty Inc (COTY) declared that Bart Becht will remain as Interim Chief Executive Officer of Coty. Mr. Becht will also continue in his role as Chairman of Coty. In connection with this change, Elio Leoni Sceti, who was planned to assume the role of CEO in July, has reconsidered and decided not to join Coty.
Coty Inc., together with its auxiliaries, manufactures, markets, and distributes women’s and mens fragrances, color cosmetics, and skin and body care related products worldwide. The company operates through three segments: Fragrances, Color Cosmetics, and Skin & Body Care. It offers various fragrance products under the Calvin Klein, Davidoff, Marc Jacobs, Chloé, Playboy, Balenciaga, Beyoncé, Bottega Veneta, Guess?, Lady Gaga Fame, Roberto Cavalli, and Katy Perry brands; and color cosmetics products, counting lip, eye, nail, and facial color products under the OPI, Rimmel, and Sally Hansen brands.
At the end of Friday’s trade, RLJ Lodging Trust (NYSE:RLJ)‘s shares dipped -0.07% to $29.83.
LJ Lodging Trust (RLJ) declared it has attained the 164-room Hyatt Place DC/Downtown/K Street in Washington, D.C. and will acquire within the next few days the 170-room Homewood Suites Seattle/Lynnwood in Lynnwood, WA for a combined purchase price of $105.9 million. The Company will use the cash accessible on its balance sheet for both acquisitions.
The Company attained the opened Hyatt Place DC/Downtown/K Street in an off-market transaction for a purchase price of $68.0 million, or about $415,000 per key. The purchase price represents a forward capitalization rate of about 7.1% on the hotel’s projected 2016 net operating income and the projected 2016 RevPAR is about 53.0% higher than the Company’s 2014 stated RevPAR. The property opened in April 2015 following an extensive renovation and conversion from an office building. Located in downtown Washington, D.C., the Hyatt Place is four blocks from three metro stations and centrally located to numerous business and leisure demand generators such as the White House, government agencies, national associations and law firms.
RLJ Lodging Trust is an independent equity real estate investment trust. The firm also manages real estate funds. It invests in the real estate markets of the United States. The firm primarily invests in premium-branded, focused service, and compact full-service hotels. RLJ Lodging Trust was launched in 2000 and is domiciled in Bethesda, Maryland.
v), ended its Friday’s trading session with 0.91% gain, and closed at $23.34.
Halozyme Therapeutics, Inc. (HALO) declared that it has reached a global partnership and license agreement with AbbVie Inc. ABBV for the development and commercialization of therapies by combining the former’s ENHANZE technology platform with the latter’s proprietary compounds.
Terms of the Deal
Per the terms of the agreement, Halozyme is entitled to receive $23 million initially. Subsequently, upon the achievement of certain development, regulatory and sales-based milestones by AbbVie, Halozyme will receive milestone payments for each of up to nine partnership targets summing up to about $130 million. In addition, Halozyme is entitled to receive tiered royalties from AbbVie upon the commercialization of products under the collaboration.
Several companies in the health care sector have been caught in the recent deal-making frenzy aimed at stepping up development of their pipelines. Last month BioNTech AG inked a deal with Genmab A/S GNMSF to jointly research, develop and commercialize antibodies for cancer immunotherapy using BioNTech’s proprietary immunomodulatory antibodies and Genmab’s DuoBody technology platform.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
